RCMI Coordinating Center (RCMI CC) Header Logo

Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.

Nguyen E, Coleman CI, Nair S, Weeda ER. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. J Diabetes Complications. 2018 02; 32(2):210-215.

View in: PubMed

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support